What is the 13F Pro Quality Score for TNGX?

13F Pro ranks Tango Therapeutics, Inc. (TNGX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TNGX's current score at https://13fpro.ai/company/TNGX (free sign-up required for the full ranking).

Which hedge funds own the most TNGX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TNGX include RTW INVESTMENTS,, BlackRock,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TNGX as soon as new 13F filings post.

Where does 13F Pro source TNGX data?

All Tango Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tango Therapeutics, Inc. files with the SEC under CIK 1819133. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TNGX in?

Tango Therapeutics, Inc. (TNGX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TNGX research updated on 13F Pro?

TNGX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tango Therapeutics, Inc.(TNGX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1819133 TNGX stock profile & AI dashboard →

13F Pro Quality Score

17.6/100

Rank #2,823 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

31.0/100

Profitability

5.2/100

Balance Sheet

11.6/100

Earnings Quality

7.4/100

Free Cash Flow

3.7/100

Institutional Flow

44.1/100

Revenue Scale

9.6/100

Dilution Risk

5.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TNGX Scores 18/100

exact factor attribution · 2026-09-11

TNGX's composite is driven by earnings growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+1.7 pts

85th pct

Institutional flow

-0.3 pts

44th pct

Shareholder dilution

-2.3 pts

5th pct

Revenue growth

-3.8 pts

31th pct

Capital efficiency

-3.8 pts

12th pct

Earnings quality

-4.3 pts

7th pct

Scale

-6.1 pts

10th pct

Profitability

-6.7 pts

5th pct

Free cash flow

-6.9 pts

4th pct

Latest change (2026-08-11): 27 → 7 · ↓ Revenue growth 87→1; ↓ Revenue scale 13→2; despite ↑ Capital efficiency 8→17

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in TNGX

Events flagged as statistical outliers against TNGX's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-11
TNGX quality score dropped 20 points (27→7) on a new filing
View source filing →

TNGX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Tango Therapeutics, Inc. (TNGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNGX at 17.6/100 on a 32-signal composite quality model, placing it at rank #2,823 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (3.7) and profitability (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Tango Therapeutics, Inc. reports net income of $-55.3M, free cash flow of $-38.9M. Top institutional holders of TNGX by reported 13-F value include RTW INVESTMENTS, BlackRock, FMR, based on the most recent SEC filings. TNGX trades on the Nasdaq exchange and files with the SEC under CIK 1819133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tango Therapeutics, Inc. directly from SEC EDGAR. Tango Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 31 since 2022, currently 17.6 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about Tango Therapeutics, Inc.

Quirks, history, and lore behind TNGX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on oncology.
2
The Numbers
A pre-revenue biotech with a relatively small market cap — the kind of company burning cash while its pipeline matures, with no approved products yet on the market.
3
The History
Founded around 2017, it was built on the premise that the next wave of cancer drugs would come from systematically identifying genetic vulnerabilities in tumors rather than chasing targets one by one.
4
The Secret
Its core platform leverages CRISPR-based functional genomics to find so-called synthetic lethal targets — genes that, when knocked out alongside a tumor mutation, cause cancer cells to self-destruct.
5
The Lore
The company was co-founded with deep ties to the Broad Institute and has partnered with Gilead Sciences, which made a significant equity investment to help advance its pipeline.
6
The Giveaway
Its name evokes a dance of precision, its ticker is a four-letter rhythm, and its lead program targets MTAP-deletion cancers — a genetic vulnerability found across multiple hard-to-treat tumor types.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-55.3M

Free Cash Flow

Q2 2026

$-38.9M

ROIC

Q2 2026

-23.3%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+48.3% YoY

$62.4MFY 2025

FY22 $24.9MFY23 $36.5MFY24 $42.1MFY25 $62.4M

Net Income

+22.0% YoY

$-101.6MFY 2025

FY22 $-108.2MFY23 $-101.7MFY24 $-130.3MFY25 $-101.6M

Operating Income

+23.6% YoY

$-111.3MFY 2025

FY22 $-111.1MFY23 $-114.2MFY24 $-145.6MFY25 $-111.3M

EPS (Diluted)

+26.9% YoY

$-0.87FY 2025

FY22 $-1.23FY23 $-1.08FY24 $-1.19FY25 $-0.87

Total Assets

+26.0% YoY

$398.7MFY 2025

FY22 $436.5MFY23 $402.6MFY24 $316.5MFY25 $398.7M

Op. Cash Flow

-5.6% YoY

$-138.9MFY 2025

FY22 $-109.1MFY23 $-118.0MFY24 $-131.5MFY25 $-138.9M

Free Cash Flow

-5.8% YoY

$-139.9MFY 2025

FY22 $-116.8MFY23 $-119.5MFY24 $-132.3MFY25 $-139.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$62.4M +48.3%	$42.1M +15.2%	$36.5M +46.9%	$24.9M -32.9%	$37.0M +383.8%	$7.7M
Net Income	$-101.6M +22.0%	$-130.3M -28.1%	$-101.7M +5.9%	$-108.2M -85.8%	$-58.2M -12.1%	$-52.0M
Operating Income	$-111.3M +23.6%	$-145.6M -27.5%	$-114.2M -2.8%	$-111.1M -90.9%	$-58.2M -11.5%	$-52.2M
EPS (Diluted)	$-0.87 +26.9%	$-1.19 -10.2%	$-1.08 +12.2%	$-1.23 -30.9%	$-0.94	—
Total Assets	$398.7M +26.0%	$316.5M -21.4%	$402.6M -7.8%	$436.5M -12.7%	$500.2M +141.3%	$207.3M
Operating Cash Flow	$-138.9M -5.6%	$-131.5M -11.5%	$-118.0M -8.2%	$-109.1M -83.2%	$-59.5M -184.9%	$70.1M
Free Cash Flow	$-139.9M -5.8%	$-132.3M -10.7%	$-119.5M -2.3%	$-116.8M -90.3%	$-61.4M -189.0%	$69.0M

Get alerted when TNGX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tango Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TNGX

RTW INVESTMENTS, LP
$434.5M13,900,620 sh
BlackRock, Inc.
$388.8M12,438,444 sh
FMR LLC
$385.5M12,333,339 sh
FARALLON CAPITAL MANAGEMENT LLC
$383.8M12,277,000 sh
Boxer Capital Management, LLC
$340.0M10,876,219 sh
GOLDMAN SACHS GROUP INC
$312.0M9,980,620 sh
TCG Crossover Management, LLC
$283.9M9,081,201 sh
Paradigm Biocapital Advisors LP
$198.7M6,357,523 sh
PRICE T ROWE ASSOCIATES INC /MD/
$198.5M6,348,827 sh
Siren, L.L.C.
$193.2M6,179,364 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$434.5M	13,900,620
BlackRock, Inc.	$388.8M	12,438,444
FMR LLC	$385.5M	12,333,339
FARALLON CAPITAL MANAGEMENT LLC	$383.8M	12,277,000
Boxer Capital Management, LLC	$340.0M	10,876,219
GOLDMAN SACHS GROUP INC	$312.0M	9,980,620
TCG Crossover Management, LLC	$283.9M	9,081,201
Paradigm Biocapital Advisors LP	$198.7M	6,357,523
PRICE T ROWE ASSOCIATES INC /MD/	$198.5M	6,348,827
Siren, L.L.C.	$193.2M	6,179,364

Companies Similar to TNGX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CGON

CG Oncology, Inc.

AI score

Very similar · 26 shared holders

RTW INVESTMENTS, LP TCG Crossover Management, LLC Seven Fleet Capital Management LP

KYMR

Kymera Therapeutics, Inc.

AI score

Very similar · 25 shared holders

Siren, L.L.C.Holocene Advisors, LP Boxer Capital Management, LLC

CYTK

CYTOKINETICS INC

AI score

Very similar · 25 shared holders

RTW INVESTMENTS, LP Holocene Advisors, LP Siren, L.L.C.

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Very similar · 17 shared holders

Paradigm Biocapital Advisors LP Deep Track Capital, LP Caligan Partners LP

IDYA

IDEAYA Biosciences, Inc.

AI score

Very similar · 24 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Logos Global Management LP Candriam S.C.A.

AVTX

Avalo Therapeutics, Inc.

AI score

Shared smart-money ownership · 20 shared holders

Deep Track Capital, LP Caligan Partners LP TCG Crossover Management, LLC

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Similar quality profile · 22 shared holders

Siren, L.L.C.PERCEPTIVE ADVISORS LLC Candriam S.C.A.

DBVT

DBV Technologies S.A.

AI score

Similar quality profile · 8 shared holders

Siren, L.L.C.Vivo Capital, LLC PERCEPTIVE ADVISORS LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TNGX on your watchlist

Track score changes the day Tango Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TNGX a good stock to buy?

13F Pro's AI-powered analysis of Tango Therapeutics, Inc. (TNGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TNGX are available on the TNGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TNGX is classified as a mid company.

Which hedge funds own TNGX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TNGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tango Therapeutics, Inc.'s investment landscape.